Prototypical Stressors

Showing 676 to 700 of 848 Prototypical Stressors

ID	Prototypical Stressor Name	Associated Chemical(s): Name, CAS-RN, DTXSID	Associated AOPs

494	S-(4-Carboxybutyl)-D,L-homocysteine; 5-(3-Amino-3-carboxypropyl)sulfanyl-pentanoic acid		301: Inhibition of Cystathionine Beta synthase leading to impaired the early development of anterior-posterior axis
146	SACCHARIN, CALCIUM SALT		None
752	SANT-1	(E)-N-(4-benzylpiperazin-1-yl)-1-(3,5-dimethyl-1-phenylpyrazol-4-yl)methanimine, CAS-RN: 304909-07-7, DTXSID90425965	460: Antagonism of Smoothened receptor leading to orofacial clefting
753	SANT-2	SANT-2, CAS-RN: 329196-48-7, DTXSID40362255	460: Antagonism of Smoothened receptor leading to orofacial clefting
754	SANT-3		460: Antagonism of Smoothened receptor leading to orofacial clefting
755	SANT-4		460: Antagonism of Smoothened receptor leading to orofacial clefting
751	SANT1		None
642	Saracatinib	Saracatinib, CAS-RN: 379231-04-6, DTXSID90191355	399: Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos)
817	Sarin		559: Inhibition of acetylcholinesterase (AChE) leading to arrhythmias
526	SARS-CoV		3 AOPs 320: Binding of SARS-CoV-2 to ACE2 receptor leading to acute respiratory distress associated mortality 377: Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Multi Organ Failure involving Acute Respiratory Distress Syndrome (ARDS) 430: Binding of SARS-CoV-2 to ACE2 leads to viral infection proliferation
619	SARS-CoV and CoV-NL63, SARS-CoV		None
624	Sars-CoV-2		6 AOPs 374: Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis 377: Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Multi Organ Failure involving Acute Respiratory Distress Syndrome (ARDS) 320: Binding of SARS-CoV-2 to ACE2 receptor leading to acute respiratory distress associated mortality 392: Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation 422: Binding of SARS-CoV-2 to ACE2 in enterocytes leads to intestinal barrier disruption 430: Binding of SARS-CoV-2 to ACE2 leads to viral infection proliferation
793	Saxitoxin		553: Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure
468	SB-210661		297: Inhibition of retinaldehyde dehydrogenase leads to population decline
476	SB216763		None
426	SC-839		None
776	Sedaxane	Sedaxane, CAS-RN: 874967-67-6, DTXSID2058207	3 AOPs 534: Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress 474: Succinate dehydrogenase inactivation leads to cancer by promoting EMT 546: Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms
51	Selected AHR Ligands		None
295	serotonin transporter activation		3 AOPs 223: Serotonin transporter activation to seizure 224: Serotonin transporter activation to depression 225: Serotonin transporter activation to agitation
233	sertraline	Sertraline, CAS-RN: 79617-96-2, DTXSID6023577	203: 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline
677	Serum	Serum, CAS-RN: NOCAS, DTXSID2041123	None
354	Sevoflurane	Sevoflurane, CAS-RN: 28523-86-6, DTXSID8046614	260: CYP2E1 activation and formation of protein adducts leading to neurodegeneration
674	Sex hormone		None
254	Silica nanoparticles		2 AOPs 209: Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP 481: AOPs of amorphous silica nanoparticles: ROS-mediated oxidative stress increased respiratory dysfunction and diseases.
711	Silver	Silver, CAS-RN: 7440-22-4, DTXSID4024305	None